A. Bois

M. von Knebel Doeberitz, N. Wentzensen, F. Kommoss, 2008, International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists.

36 Paclitaxel/Carboplatin(TC) vs Paclitaxel/Carboplatin sequentially followed by Topotecan (TC-Top) in first-line treatment of ovarian cancer Flgo stages IIB – IV interim results of a gynaecologic cancer intergroup phase III trial of the Ago ovarian cancer study group and Gineco

R. Kimmig, B. Weber, S. Costa, 2003 .

PARP inhibition: opening up new horizons?

F. Heitz, A. Bois, 2011 .

Treatment of patients with advanced ovarian cancer (FIGO IIb-IV) with cisplatin/paclitaxel or carboplatin/paclitaxel — An interim analysis of the ago study protocol ovar-3

U. Nitz, W. Kuhn, H. Lück, 1999 .

ICON4/AGO-OVAR-2.2: questions about trial design, cost-effectiveness, and clinical benefit

V. Torri, J. Ledermann, N. Colombo, 2003, The Lancet.

Consensus Statement on pre- operative diagnosis of ovarian tumors

T. Bourne, D. Timmerman, N. Concin, 2021 .

The biological and clinical value of p53 expression in pelvic high‐grade serous carcinomas

A. Reuss, D. Huntsman, M. Köbel, 2010, The Journal of pathology.

ESGO consensus conference recommendations on ovarian cancer : pathology and molecular biology , early and advanced stages , borderline tumours and recurrent disease

J. Ledermann, I. Vergote, I. McNeish, 2019 .

Cellular DNA content and survival in advanced ovarian carcinoma

W. Sauerbrei, F. Kommoss, J. Pfisterer, 1994, Cancer.

Impact of treatment characteristics on response of different breast cancer phenotypes: pooled analysis of the German neo-adjuvant chemotherapy trials

P. Fasching, W. Eiermann, S. Loibl, 2010, Breast Cancer Research and Treatment.

Androgen receptor expression in primary breast cancer and its predictive and prognostic value in patients treated with neoadjuvant chemotherapy

Carsten Denkert, Keyur Mehta, Bernd Gerber, 2011, Breast Cancer Research and Treatment.

Paclitaxel/carboplatin (TC) vs. paclitaxel/carboplatin followed by topotecan (TOP) in first-line treatment of advanced ovarian cancer. Mature results of a Gynecologic Cancer Intergroup phase III trial of the AGO OVAR and GINECO

C. Schade-Brittinger, B. Weber, C. Jackisch, 2005 .

Quality of life and sexual function in patients with borderline tumors of the ovary. A substudy of the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) study group ROBOT study

A. Reuss, C. Fotopoulou, A. Hasenburg, 2014, Supportive Care in Cancer.

Systematic pelvic and paraaortic lymphadenectomy in early high-risk or advanced endometrial cancer

J. Sehouli, C. Fotopoulou, F. Heitz, 2015, Archives of Gynecology and Obstetrics.

Skeletal Muscle Attenuation (Sarcopenia) Predicts Reduced Overall Survival in Patients with Advanced Epithelial Ovarian Cancer Undergoing Primary Debulking Surgery

J. Koch, B. Ataseven, K. Waltering, 2018, Annals of Surgical Oncology.

Surgery in Recurrent Ovarian Cancer: The Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) DESKTOP OVAR Trial

J. Huober, J. Sehouli, A. Hasenburg, 2006, Annals of Surgical Oncology.

LION: Lymphadenectomy in ovarian neoplasms—A prospective randomized AGO study group led gynecologic cancer intergroup trial.

A. Reuss, R. Kimmig, I. Vergote, 2017 .

Prognostic Impact of Additional Extended Surgical Procedures in Advanced-Stage Primary Ovarian Cancer

F. Heitz, P. Harter, J. Barinoff, 2009, Annals of Surgical Oncology.

A Novel Two-Lipid Signature Is a Strong and Independent Prognostic Factor in Ovarian Cancer

M. Hilvo, S. Hietanen, J. Sehouli, 2021, Cancers.

Prognostic Value of the Age-Adjusted Charlson Comorbidity Index (ACCI) on Short- and Long-Term Outcome in Patients with Advanced Primary Epithelial Ovarian Cancer

B. Ataseven, F. Heitz, P. Harter, 2017, Annals of Surgical Oncology.

Low-grade Serous Tumors: Are We Making Progress?

B. Ataseven, F. Heitz, P. Harter, 2020, Current Oncology Reports.

828P Expected versus observed response to platinum-based chemotherapy after poly (ADP-ribose) polymerase inhibitor treatment for relapsed ovarian cancer

N. Concin, B. Ataseven, F. Heitz, 2020 .

BRCA1 Germline Mutation in a Woman with Metaplastic Squamous Cell Breast Cancer

C. Sutter, H. Lück, M. Kandel, 2007, Oncology Research and Treatment.

5-Hydroxyindoleacetic acid excretion following combination chemotherapy with cyclophosphamide, epirubicin and 5-fluorouracil plus ondansetron compared to ondansetron alone

W. Vach, A. Bois, R. Holy, 1996, Supportive Care in Cancer.

Evaluation of new antiemetic agents and definition of antineoplastic agent emetogenicity—an update

D. Osoba, M. Tonato, R. Gralla, 2005, Supportive Care in Cancer.

Phase II study of pirarubicin combined with cisplatin in recurrent ovarian cancer

T. Bauknecht, P. Dall, H. Madjar, 2005, Journal of Cancer Research and Clinical Oncology.

Capecitabine plus paclitaxel versus epirubicin plus paclitaxel as first-line treatment for metastatic breast cancer: efficacy and safety results of a randomized, phase III trial by the AGO Breast Cancer Study Group

M. Beckmann, S. Loibl, T. Schuster, 2013, Breast Cancer Research and Treatment.

A multicentre phase II study on gefitinib in taxane- and anthracycline-pretreated metastatic breast cancer

P. Fasching, A. Schneeweiss, W. Eiermann, 2004, Breast Cancer Research and Treatment.

Randomized, multicenter, two-dose level, open-label, phase IIa study with the intraperitoneally infused trifunctional bispecific antibody catumaxomab (anti-EpCAM x anti-CD3) to select the better dose level in platinum refractory epithelial ovarian cancer patients

S. Loibl, N. Burchardi, I. Vergote, 2007 .

Why Institutions Do not Participate in Ovarian Cancer Trials – Results from a Survey in Germany

J. Sehouli, D. Stengel, A. Bois, 2004, Oncology Research and Treatment.

Outcome of patients with borderline ovarian tumors: Results of the multicenter AGO ROBOT study.

A. Reuss, S. Hauptmann, C. Fotopoulou, 2012 .

The Value of Serum CA 125 in the Diagnosis of Borderline Tumors of the Ovary

T. Fehm, A. Reuss, S. Hauptmann, 2015 .

Randomized phase III study to evaluate the impact of secondary cytoreductive surgery in recurrent ovarian cancer – final analysis of AGO DESKTOP III/ENGOT- ov20

A. Reuss, F. Guyon, I. Vergote, 2020, Geburtshilfe und Frauenheilkunde.

Struma ovarii recurrence with peritoneal strumosis: A case report

F. Heitz, P. Harter, C. Menzel, 2012 .

Stage- and Histologic Subtype-Dependent Frequency of Lymph Node Metastases in Patients with Epithelial Ovarian Cancer Undergoing Systematic Pelvic and Paraaortic Lymphadenectomy

B. Ataseven, F. Heitz, P. Harter, 2018, Annals of Surgical Oncology.

Syndrome of Inappropriate ADH Secretion (SIADH) During Chemotherapy with Carboplatin/Paclitaxel for Metastatic Fallopian Tube Cancer

F. Grabellus, P. Harter, C. Grimm, 2015 .

Influence of Residual Tumor on Outcome in Ovarian Cancer Patients With FIGO Stage IV Disease

Jacobus Pfisterer, Philipp Harter, Rainer Kimmig, 2010, Annals of Surgical Oncology.

Surgical Procedures After Neoadjuvant Chemotherapy in Operable Breast Cancer: Results of the GEPARDUO Trial

S. Loibl, J. Blohmer, C. Jackisch, 2006, Annals of Surgical Oncology.

A stochastic model to analyse risk factors for emesis in multi-cycle chemotherapies

W. Vach, A. Bois, Kirstin Schulz, 2001 .

1 Requirements to Assess Feasibility of Phase 0 Trials during Major Abdominal Surgery - Variability of Poly(ADP-Ribose) Polymerase Activity.

F. Heitz, P. Harter, J. Barinoff, 2012 .

Compliance to consensus recommendations, surgeon's experience and introduction of a quality assurance and management program. – Influence on therapy of early-stage ovarian carcinoma

P. Harter, S. Kommoss, A. Bois, 2008 .

Band 22, Heft 4, August 1999

J. Serth, W. Scheithauer, T. Bauknecht, 1999, Oncology Research and Treatment.

Early prediction of the platinum-resistant relapse risk using the CA125 modeled kinetic parameter KELIM: A pooled analysis of AGO-OVAR 7 & 9; ICON 7 (AGO/GINECO/ MRC CTU/GCIG trials)

I. Ray-Coquard, A. Leary, A. Burges, 2019, Annals of Oncology.

Two prognostic populations of ovarian cancer patients defined by CA125 modeled kinetic parameter KELIM (AGO-OVAR 7 & 9; ICON 7 AGO/GINECO/ MRC CTU/GCIG trials).

I. Ray-Coquard, A. Leary, A. Bessard, 2017 .

The predictive value of the CA-125 modeled kinetic parameter KELIM is validated in 3 independent datasets (AGO-OVAR 7 & 9; ICON 7 AGO/GINECO/GCIG trials)

J. Huober, I. Ray-Coquard, W. Meier, 2016 .

Genome-wide association study (GWAS) of pazopanib efficacy and safety in patients with ovarian cancer who have not progressed following first-line standard therapy.

B. Monk, Chun-Fang Xu, T. Johnson, 2014 .

ASO Author Reflections: Systematic Lymph Node Dissection in Ovarian Cancer Under Attack

F. Heitz, P. Harter, A. Bois, 2018, Annals of Surgical Oncology.

Additional prognostic value of lymph node ratio over pN staging in different breast cancer subtypes based on the results of 1,656 patients

J. Blohmer, S. Kümmel, B. Ataseven, 2015, Archives of Gynecology and Obstetrics.

2004 consensus statements on the management of ovarian cancer: final document of the 3rd International Gynecologic Cancer Intergroup Ovarian Cancer Consensus Conference (GCIG OCCC 2004).

E. Trimble, M. Parmar, E. Eisenhauer, 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

Homologous recombination repair mutation gene panels (excluding BRCA) are not predictive of maintenance olaparib plus bevacizumab efficacy in the first-line PAOLA-1/ENGOT-ov25 trial

D. Berton, I. Vergote, S. Pignata, 2021, Gynecologic Oncology.

Ten-year results of intense dose-dense chemotherapy show superior survival compared with a conventional schedule in high-risk primary breast cancer: final results of AGO phase III iddEPC trial

N Harbeck, C Thomssen, A. Schneeweiss, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Ovarian Carcinoma: Clinical Validity by Simultaneous Determination of Fibrin Degradation Products with the DR-70™ Immunoassay and CA-125

P. Harter, A. Bois, J. Mainz, 2006 .

GWAS meta-analysis and replication identifies three new susceptibility loci for ovarian cancer

Brooke L. Fridley, Matthias W. Beckmann, Peter A. Fasching, 2013, Nature Genetics.

Final analysis of the prospective WSG-AGO EC-Doc versus FEC phase III trial in intermediate-risk (pN1) early breast cancer: efficacy and predictive value of Ki67 expression.

D. Wallwiener, R. Kreienberg, M. Kiechle, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Operative and Conservative Treatment of Uterine Sarcomas.

F. Heitz, P. Harter, A. du Bois, 2014, Geburtshilfe und Frauenheilkunde.

Topotecan weekly versus routine 5-day schedule in patients with platinum-resistant ovarian cancer (TOWER): A randomized, two-stage phase-II study of the North-Eastern German Society of Gynaecological Oncology (NOGGO)

S. Loibl, W. Lichtenegger, J. Sehouli, 2007 .

Predictors of survival in patients with recurrent ovarian cancer undergoing secondary cytoreductive surgery based on the pooled analysis of an international collaborative cohort

J. Berek, D. Chi, J. Sehouli, 2011, British Journal of Cancer.

ESMO-ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease†.

D. Timmerman, J. Ledermann, R. Glasspool, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

S3-Guideline on Diagnostics, Therapy and Follow-up of Malignant Ovarian Tumours: Short version 1.0 - AWMF registration number: 032/035OL, June 2013.

A. Reuss, S. Hauptmann, N. Arnold, 2013, Geburtshilfe und Frauenheilkunde.

Fifth Ovarian Cancer Consensus Conference of the Gynecologic Cancer InterGroup: recurrent disease

A. Reuss, A. Oza, A. Okamoto, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

Re-operation outcome in patients referred to a gynecologic oncology center with presumed ovarian cancer FIGO I-IIIA after sub-standard initial surgery.

D. Lorenz, P. Harter, A. du Bois, 2012, Surgical oncology.

Feasibility, toxicity and quality of life of first-line chemotherapy with platinum/paclitaxel in elderly patients aged >or=70 years with advanced ovarian cancer--a study by the AGO OVAR Germany.

S. Loibl, A. du Bois, J. Hedderich, 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

The anti-idiotypic antibody abagovomab in patients with recurrent ovarian cancer. A phase I trial of the AGO-OVAR.

A. Reuss, R. Kimmig, S. Loibl, 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

39 Topotecan versus treosulfan in recurrent ovarian cancer after initial chemotherapy with platinum and paclitaxel. a prospective randomised phase III study of the AGO ovarian cancer study group

R. Kimmig, S. Loibl, W. Kuhn, 2003 .

Cisplatin/paclitaxel vs. carboplatin/paclitaxel in 798 patients with ovarian cancer FIGO IIB-IV — Randomized phase III study the AGO (Arbeitsgemeinschaft Gynaekologische Onkologie) study group (OVAR-3 trial)

T. Bauknecht, S. Costa, W. Meier, 2001 .

PALB2,CHEK2 and ATM rare variants and cancer risk: Data from COGS

Jane E. Carpenter, Lara E Sucheston-Campbell, Ali Amin Al Olama, 2016 .

Prognostic Factors for Local, Loco-regional and Systemic Recurrence in Early-stage Breast Cancer

J. Blohmer, S. Kümmel, B. Ataseven, 2015, Geburtshilfe und Frauenheilkunde.

Small cell of the ovary, hypercalcemic type -- analysis of combined experience and recommendation for management. A GCIG study.

J. Ledermann, G. Rustin, M. Friedlander, 2006, Gynecologic oncology.

Advanced epithelial ovarian cancer: 1998 consensus statements.

M. Parmar, E. Eisenhauer, M. Gore, 1999, Annals of oncology : official journal of the European Society for Medical Oncology.

Pathophysiology, severity, pattern, and risk factors for carboplatin-induced emesis.

W. Vach, M. Kiechle, A. du Bois, 1996, Oncology.

Cerebral metastases in metastatic breast cancer: disease-specific risk factors and survival.

F. Heitz, P. Harter, A. du Bois, 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

Ovarian cancer—can intraperitoneal therapy be regarded as new standard in Germany?

J. Sehouli, A. du Bois, W. Meier, 2006, International Journal of Gynecologic Cancer.

Can intraperitoneal chemotherapy be regarded as a new standard in advanced ovarian cancer

J. Sehouli, W. Meier, B. Schmalfeldt, 2006 .

Clinical trials in ovarian carcinoma: requirements for standard approaches and regimens.

H. Kitchener, D. Provencher, M. Friedlander, 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

Open-label feasibility study of pazopanib, carboplatin, and paclitaxel in women with newly diagnosed, untreated, gynaecologic tumours: a phase I/II trial of the AGO study group

I. Vergote, I. Ray-Coquard, P. Harter, 2012, British Journal of Cancer.

Obesity and survival among women with ovarian cancer: results from the Ovarian Cancer Association Consortium

A. Whittemore, P. Fasching, R. Vierkant, 2015, British Journal of Cancer.

Prognostic impact of the time interval between surgery and chemotherapy in advanced ovarian cancer: analysis of prospective randomised phase III trials.

A. Reuss, I. Ray-Coquard, K. Wegscheider, 2013, European journal of cancer.

Combination therapy with gemcitabine and carboplatin in recurrent ovarian cancer

E. Eisenhauer, I. Vergote, A. du Bois, 2004, International Journal of Gynecologic Cancer.

A phase I open-label dose-escalation study of oral BIBF 1120 combined with standard paclitaxel and carboplatin in patients with advanced gynecological malignancies.

S. Loibl, J. Huober, P. Harter, 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase I/II study of the combination of carboplatin and paclitaxel as first-line chemotherapy in patients with advanced epithelial ovarian cancer.

T. Bauknecht, A. du Bois, H. Lück, 1997, Annals of oncology : official journal of the European Society for Medical Oncology.

Chemotherapy may be more effective in highly proliferative ovarian carcinomas--a translational research subprotocol of a prospective randomized phase III study (AGO-OVAR 3 protocol).

R. Parwaresch, A. du Bois, F. Kommoss, 2006, Gynecologic oncology.

A phase II trial (AGO 2.11) in platinum-resistant ovarian cancer: a randomized multicenter trial with sunitinib (SU11248) to evaluate dosage, schedule, tolerability, toxicity and effectiveness of a multitargeted receptor tyrosine kinase inhibitor monotherapy.

P. Hillemanns, J. Rau, J. Sehouli, 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

Independent prognostic significance of cell cycle regulator proteins p16INK4a and pRb in advanced-stage ovarian carcinoma including optimally debulked patients: a translational research subprotocol of a randomised study of the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group

A. du Bois, R. Ridder, F. Kommoss, 2007, British Journal of Cancer.

Long-term safety in patients with recurrent ovarian cancer treated with niraparib versus placebo: Results from the phase III ENGOT-OV16/NOVA trial.

I. Vergote, U. Matulonis, S. Lau, 2020, Gynecologic oncology.

Quality of life in patients with advanced epithelial ovarian cancer (EOC) randomized to maintenance pazopanib or placebo after first-line chemotherapy in the AGO-OVAR 16 trial. Measuring what matters—patient-centered end points in trials of maintenance therapy

B. Monk, M. King, M. Friedlander, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

Frequency, severity and timing of common adverse events (AEs) with maintenance olaparib in patients (pts) with platinum-sensitive relapsed serous ovarian cancer (PSR SOC).

D. Matei, J. Ledermann, C. Scott, 2015 .

VEGF-A and i-NOS expression are prognostic factors in serous epithelial ovarian carcinomas after complete surgical resection

S. Loibl, V. Nekljudova, K. Engels, 2009, Journal of Clinical Pathology.

ESMO–ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease

J. Ledermann, I. Vergote, I. McNeish, 2019, International Journal of Gynecological Cancer.

Treatment of recurrent ovarian cancer.

S. Pignata, F. Heitz, P. Harter, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

Genome-wide significant risk associations for mucinous ovarian carcinoma

Yurii B. Shvetsov, A. Whittemore, L. Kiemeney, 2015, Nature Genetics.

Phase I/II study of the combination of carboplatin and paclitaxel as first-line chemotherapy in patients with advanced epithelial ovarian cancer.

T. Bauknecht, V. Möbus, A. Bois, 1997, Annals of oncology : official journal of the European Society for Medical Oncology.

Age-dependent differences in borderline ovarian tumours (BOT) regarding clinical characteristics and outcome: results from a sub-analysis of the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) ROBOT study.

T. Fehm, A. Reuss, S. Hauptmann, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Second-line carboplatin and gemcitabine in platinum sensitive ovarian cancer--a dose-finding study by the Arbeitsgemeinschaft Gynäkologische Onkologie (AGO) Ovarian Cancer Study Group.

R. Kimmig, J. Blohmer, A. du Bois, 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

Advanced epithelial ovarian cancer: 1998 consensus statements.

J. Neijt, G. Rustin, J. Berek, 1993 .

Clinical research in epithelial ovarian cancer and patients' outcome.

A. du Bois, J. Rochon, A. Bois, 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

Platinum versus platinum-combination chemotherapy in platinum-sensitive recurrent ovarian cancer: a meta-analysis using individual patient data.

M. Parmar, J. Ledermann, I. Vergote, 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

Genome-wide significant risk associations for mucinous ovarian carcinoma

Yurii B. Shvetsov, A. Whittemore, L. Kiemeney, 2015, Nature Genetics.

Pegfilgrastim +/- ciprofloxacin for primary prophylaxis with TAC (docetaxel/doxorubicin/cyclophosphamide) chemotherapy for breast cancer. Results from the GEPARTRIO study.

W. Eiermann, S. Loibl, S. Kümmel, 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

Correlation of various pathologic complete response (pCR) definitions with long-term outcome and the prognostic value of pCR in various breast cancer subtypes: Results from the German neoadjuvant meta-analysis.

P. Fasching, W. Eiermann, S. Loibl, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Skeletal Muscle Attenuation (Sarcopenia) Predicts Reduced Overall Survival in Patients with Advanced Epithelial Ovarian Cancer Undergoing Primary Debulking Surgery

J. Koch, B. Ataseven, K. Waltering, 2018, Annals of Surgical Oncology.

Clinicopathological differences between breast cancer in patients with primary metastatic disease and those without: a multicentre study.

F. Heitz, P. Harter, A. du Bois, 2013, European journal of cancer.

Chemotherapy versus hormonal treatment in platinum- and paclitaxel-refractory ovarian cancer: a randomised trial of the German Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) Study Group Ovarian Cancer.

T. Bauknecht, C. Jackisch, S. Costa, 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

Prognosis Factors for Breast Cancer Recurrence in a Collective of the HSK Wiesbaden 1998 - 2003

H. Lück, A. Fisseler‐Eckhoff, A. Bois, 2008 .

Final analysis of the prospective WSG-AGO EC-Doc versus FEC phase III trial in intermediate-risk (pN1) early breast cancer: efficacy and predictive value of Ki67 expression.

D. Wallwiener, R. Kreienberg, N. Harbeck, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

HIPEC: HOPE or HYPE in the fight against advanced ovarian cancer?

I. Vergote, J. Sehouli, L. Chiva, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Pattern and clinical predictors of lymph node metastases in epithelial ovarian cancer

P. Harter, A. du Bois, A. Fisseler‐Eckhoff, 2006, International Journal of Gynecologic Cancer.

Management of borderline ovarian tumors.

F. Heitz, P. Harter, A. du Bois, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

Pattern of care and impact of participation in clinical studies on the outcome in ovarian cancer

A. du Bois, J. Rochon, J. Pfisterer, 2004, International Journal of Gynecologic Cancer.

Anthracycline and trastuzumab in breast cancer treatment.

D. Wallwiener, R. Kreienberg, N. Harbeck, 2004, Oncology.

The role of surgery in recurrent ovarian cancer

S. Loibl, J. Huober, C. Jackisch, 2005, International Journal of Gynecologic Cancer.

PALB2,CHEK2 and ATM rare variants and cancer risk: Data from COGS

Dong Liang, Jane E. Carpenter, Peter Kraft, 2016 .

Docetaxel and carboplatin as first-line chemotherapy in patients with advanced gynecological tumors. A phase I/II trial of the Arbeitsgemeinschaft Gynäkologische Onkologie (AGO-OVAR) Ovarian Cancer Study Group.

D. Wallwiener, J. Blohmer, A. du Bois, 2004, Gynecologic oncology.

Final analysis of the prospective WSG-AGO EC-Doc versus FEC phase III trial in intermediate-risk (pN1) early breast cancer: efficacy and predictive value of Ki67 expression.

D. Wallwiener, R. Kreienberg, M. Kiechle, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

When should Surgery be used for Recurrent Ovarian Carcinoma?

F. Heitz, P. Harter, A. du Bois, 2018, Clinical oncology (Royal College of Radiologists (Great Britain)).

The role of surgery in advanced and recurrent ovarian cancer.

P. Harter, A. du Bois, A. Bois, 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

Statement by the Kommission OVAR of the AGO Study Group on the Use of HIPEC (Hyperthermic Intraperitoneal Chemotherapy) to Treat Primary and Recurrent Ovarian Cancer.

I. Runnebaum, J. Sehouli, O. Ortmann, 2013, Geburtshilfe und Frauenheilkunde.

Ovarialkarzinom : Klinische Validität bei simultaner Messung von Fibrin-Degradationsprodukten mit dem DR-70 TM Immunoassay und CA-125 als

P. Harter, A. Bois, P. Harter, 2022 .